Genetically engineered Salmonella Typhimurium Recent advances in cancer<br>基因工程鼠伤寒沙门氏菌的最新研究进展-YB1港药溶溜
中 | EN
  • HOME
  • ABOUT US
    • Company profile
    • Memorabilia
    • Management team
    • Shareholder
    • Contact us
  • YB1 LEARNING ZONE
    • YB1 Papers
    • YB1 Headlines
    • YB1 Media
  • R&D AND PRODUCTS
    • Core technology
    • Products
    • Highlights
    • Patents
  • NEWS
    • Company news
    • Information
HOME > YB1 Papers

Genetically engineered Salmonella Typhimurium Recent advances in cancer
基因工程鼠伤寒沙门氏菌的最新研究进展

论文出处:ResearchGate
发表时间:2019.2.1

Source: ResearchGate
Published: 2019.2.1

【View PDF】
  • Last:IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella
    IFN-γ依赖性NK细胞的激活对工程沙门氏菌抑制转移至关重要?
  • Next:Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct
    抗血管生成肽与携带Sox2 shRNA构建体的沙门氏菌VNP20009联合使用可增强体内对肺癌的治疗效果
  • ABOUT US
    Company profile
    Memorabilia
    Management team
    Shareholder
    Contact us
  • YB1 LEARNING ZONE
    YB1 Papers
    YB1 Headlines
    YB1 Media
  • R&D AND PRODUCTS
    Core technology
    Products
    Highlights
    Patents
  • NEWS
    Company news
    Information
website:www.yb1bio.com
mailbox:info@yb1bio.com
Address: 8 / F, Jindi center, 2007 Shennan Avenue, Futian District, Shenzhen
@2011-2021 HKND YB1 PHARMACEUTICAL LIMITED
粤ICP备2021121218号-1